NASDAQ:IMNN
Imunon, Inc. Stock News
$1.38
-0.130 (-8.61%)
At Close: May 10, 2024
IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
11:00am, Monday, 06'th May 2024
LAWRENCEVILLE, N.J., May 06, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacci
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
05:00pm, Thursday, 21'st Mar 2024
LAWRENCEVILLE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vac
Imunon, Inc. (IMNN) Q3 2023 Earnings Call Transcript
06:29pm, Friday, 17'th Nov 2023
Imunon, Inc. (NASDAQ:IMNN ) Q3 2023 Earnings Call Transcript November 14, 2023 10:00 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Corinne Le Goff - President & Chief Executive Off
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
08:30am, Tuesday, 07'th Nov 2023
LAWRENCEVILLE, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc
IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress
08:30am, Monday, 23'rd Oct 2023
Highlights advantages of IMUNON's PlaCCine modality over current commercial vaccines LAWRENCEVILLE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage biotechnology
IMUNON to Participate in the H.C. Wainwright Global Investment Conference
08:30am, Tuesday, 05'th Sep 2023
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology company, announces that management will participate in the H.C. Wainwright 25th Annu
Imunon, Inc. (IMNN) Q2 2023 Earnings Call Transcript
03:46am, Sunday, 13'th Aug 2023
Imunon, Inc. (NASDAQ:IMNN ) Q2 2023 Earnings Conference Call August 10, 2023 11:00 AM ET Company Participants Corinne Le Goff – President, Chief Executive Officer Jeffrey Church - Chief Financial Of
IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
08:30am, Thursday, 03'rd Aug 2023
LAWRENCEVILLE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vacc
IMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
08:30am, Thursday, 23'rd Mar 2023
LAWRENCEVILLE, N.J., March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vac
Imunon, Inc. (IMNN) Q3 2022 Earnings Call Transcript
11:33am, Wednesday, 16'th Nov 2022
Imunon, Inc. (NASDAQ:IMNN ) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Kim Golodetz - Investor Relations Corinne Le Goff - President and Chief Executive Office
Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
08:30am, Monday, 07'th Nov 2022
LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, announ
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
06:30pm, Monday, 12'th Sep 2022
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executiv
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09:15am, Wednesday, 07'th Sep 2022
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Exe
Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript
03:31pm, Monday, 15'th Aug 2022
Celsion Corporation (NASDAQ:CLSN ) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne
Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022
08:30am, Monday, 08'th Aug 2022
LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, annou
